LICENSING PORTFOLIO

PDL’s humanization technology licensing portfolio is among the most successful and profitable in the history of the U.S. biotechnology industry. At its foundation is our intellectual property platform, which is widely commercially validated and recognized, and has generated significant royalties from some of the leading companies in the industry.

Currently, we receive royalties on a number of marketed products that utilize this technology and there are numerous other humanized antibodies in late stage clinical trials, some of which may be under license to PDL. 

Companies currently holding patent licenses for marketed products include:

• Genentech, Inc.:  Herceptin® (trastuzumab),  Xolair® (omalizumab),  Raptiva®    (efalizumab), Avastin® (bevacizumab), and Lucentis® (ranibizumab injection) 
• MedImmune, LLC:  Synagis® (palivizumab)
• Wyeth:  Mylotarg® (gemtuzumab ozogamicin)
• Elan/Biogen Idec: Tysabri® (natalizumab)
• Chugai/Roche: Actemra (tocilizumab)
• UCB Celltech: Cimzia (certolizumab)